VMValentina Milani

Valentina Milani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Valentina Milani has a total of 305 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Dynamics of the lncRNA BACE1-AS and β-Amyloid in Ischemic Heart Disease

    by Simona Greco, Michela Gottardi Zamperla, Federico Favretto, Valentina Milani, Luca Testa, Francesco Bedogni, Aleksa Petković, Iva Perović Blagojević, Dalibor Dragišić, Maurizio Bussotti, et al.

    BackgroundIschemia-driven molecular remodeling is central to acute coronary syndrome (ACS) and ischemic heart failure (IHF). The long noncoding RNA (lncRNA) BACE1-AS regulates the β-secretase gene (BACE1) and β-amyloid (Aβ1–40) production, linking ischemia to amyloidogenic stress. However, the translational relevance of this pathway remains incompletely defined. We investigated the BACE1-AS/BACE1/Aβ1–40 axis as a biomarker across ischemic heart diseases.MethodsWe analyzed BACE1-AS expression in peripheral blood mononuclear cells (PBMCs) and circulating Aβ1–40 levels in plasma from ACS patients, IHF patients, and healthy controls. Samples were collected at admission and, for ACS patients, at 12-month follow-up. Gene expression was quantified by RT-qPCR and Aβ1–40 by ELISA. Associations with clinical variables, cardiac function, and outcomes were assessed using multivariate models and ROC curve analysis.

  • Open Access

    Diagnostic potential of circular RNAs in carotid atherosclerotic plaque vulnerability

    by Simona Greco, Federica Perego, Santiago Nicolas Piella, Federico Favretto, Spyros Tastsoglou, Valentina Milani, Sara Boveri, Laura Valentina Renna, Rosanna Cardani, Federico Ambrogi, et al.

    Vulnerable carotid atherosclerotic plaques are prone to cap rupture and thrombosis, yet definitive assessment still relies on postoperative histology. We investigated whether circulating circular RNAs (circRNAs) in peripheral blood mononuclear cells (PBMCs) can identify plaque vulnerability preoperatively. In patients undergoing carotid endarterectomy, plaques were classified as vulnerable or stable, and PBMC expression of candidate circRNAs (circVIRMA, circGRN, circANRIL and CDR1as) and paired linear transcripts was quantified by RT-qPCR. A composite in-plaque_SCORE (IL-1β, IL-6, IL-10, PPARγ mRNAs) characterized intraplaque inflammation. We derived two PBMC metrics: circRNA_SCORE (mean expression of deregulated circRNAs) and circ/linear mRNA_SCORE (mean of circ/linear mRNA expression ratios) and evaluated diagnostic performance by Receiver Operating Characteristic curve (ROC) analysis and logistic regression. circVIRMA and circGRN were modestly increased in PBMCs from patients with vulnerable plaques, whereas linear host genes were unchanged. CDR1as was markedly upregulated and showed the strongest discrimination among the other circRNAs, similarly to the circRNA_and circRNA/linear mRNA ratio_SCOREs. Indeed, circRNA_SCORE correlated positively with the intraplaque inflammatory in-plaque_SCORE, linking systemic signatures to local plaque biology. In plaque tissue, CDR1 mRNA was reduced while CDR1as was relatively preserved, yielding a higher CDR1as/CDR1 mRNA ratio in vulnerable lesions. PBMC circRNAs—particularly CDR1as—show promise as noninvasive biomarkers of carotid plaque vulnerability and reflect plaque inflammatory status. Validation in independent cohorts and integration with imaging could enable improved preoperative risk stratification.


  • Open Access

    Open-bore MRI Scanner Assessment of Epicardial Adipose Tissue after Bariatric Surgery: A Pilot Study

    by Carmela Asteria, Francesco Secchi, Lelio Morricone, Alexis Elias Malavazos, Simona Francesconi, Valentina Milani, Alessandro Giovanelli

    Background: The recognition of epicardial adipose tissue (EAT) as a cardiac risk factor has increased the interest in strategies that target cardiac adipose tissue. Aim: The effect of bariatric and metabolic surgery (BMS)-induced weight loss on EAT volume was evaluated in this study. Methods: Fifteen bariatric patients, with (MS) or without (wMS) Metabolic Syndrome, underwent magnetic resonance imaging (MRI) using an open-bore scanner to assess EAT volume, visceral adipose tissue (VAT) thickness, and other cardiac morpho-functional parameters at baseline and 12 months after BMS. Nine patients underwent laparoscopic sleeve gastrectomy (LSG), and 6 patients underwent Roux-en-Y Gastric Bypass (RYGBP). Results: EAT volume significantly decreased in all the patients 12 months post-BMS from 91.6 cm3 to 67.1 cm3; p = 0.0002 in diastole and from 89.4 cm3 to 68.2 cm3; p = 0.0002 in systole. No significant difference was found between the LSG and RYGBP group. Moreover, EAT volume was significantly reduced among wMS compared with MS. In particular, EAT volume in diastole was significantly reduced from 80.9 cm3 to 54.4 cm3; p = 0.0156 in wMS and from 98.3 cm3 to 79.5 cm3; p = 0.031 in MS. The reduction was also confirmed in systole from 81.2 cm3 to 54.1 cm3; p = 0.0156 in wMS and from 105.7 cm3 to 75.1 cm3; p = 0.031 in MS. Finally, a positive correlation was found between EAT loss, BMI (r = 0.52; p = 0.0443) and VAT (r = 0.66; p = 0.008) reduction after BMS. Conclusion: These findings suggest that EAT reduction may be a fundamental element for improving the cardio-metabolic prognosis of bariatric patients. Moreover, this is the first study performed with an open-bore MRI scanner to measure EAT volume.


  • Open Access

    Comparative outcomes of Toupet fundoplication and magnetic sphincter augmentation

    by Emanuele Asti, Pamela Milito, Caterina Froiio, Valentina Milani, Luigi Bonavina

    Laparoscopic fundoplication is the current surgical gold standard for the treatment of refractory gastroesophageal reflux disease (GERD). Magnetic sphincter augmentation (MSA) is a less invasive, standardized, and reversible option to restore competency of the lower esophageal sphincter. A comparative cohort study was conducted at a tertiary-care referral center on patients with typical GERD symptoms treated with systematic crural repair combined with Toupet fundoplication or MSA. Primary study outcome was decrease of Gastroesophageal Reflux Disease-Health Related Quality of Life (GERD-HRQL) score. Between January 2014 and December 2021, a total of 199 patients (60.3% female, median [Q1–Q3] age: 51.0 [40.0–61.0]) underwent MSA (n = 130) or Toupet fundoplication (n = 69). Operative time and hospital stay were significantly shorter in MSA patients (P < 0.0001). At a median follow-up of 12.0 [12.0–24.0] months, there was a statistically significant decrease of GERD-HRQL score in both patient groups (P = 0.001). The mean delta values did not significantly differ between groups (P = 0.7373). The incidence of severe gas bloating symptoms was similar in the two groups (P = 0.7604), but the rate of persistent postoperative dysphagia was greater in MSA patients (P = 0.0009). Six (8.7%) patients in the Toupet group had recurrent hiatal hernia requiring revisional surgery in one (1.4%). In the MSA group, eight (7.9%) patients necessitated through-the-scope balloon dilation for relief of dysphagia, and six patients had the device removed (4.6%) because of persistent dysphagia (n = 3), device disconnection (n = 1), persistent reflux (n = 1) or need of magnetic resonance (n = 1). Toupet and MSA procedures provide similar clinical outcomes, but MSA is associated with a greater risk of reoperation. Randomized clinical trials comparing fundoplication and MSA are eagerly awaited.


  • Could fat distribution have a greater influence than BMI on the antibody titre after SARS‐CoV‐2 vaccine?

    by Sara Basilico, Carola Dubini, Valentina Milani, Caterina Bertolini, Alexis Elias Malavazos


  • Open Access

    Antibody responses to BNT162b2 mRNA vaccine: Infection‐naïve individuals with abdominal obesity warrant attention

    by Alexis Elias Malavazos, Sara Basilico, Gianluca Iacobellis, Valentina Milani, Rosanna Cardani, Federico Boniardi, Carola Dubini, Ilaria Prandoni, Gloria Capitanio, Laura Valentina Renna, et al.

    Objective: The excess of visceral adipose tissue might hinder and delay immune response. How people with abdominal obesity (AO) will respond to mRNA vaccines against SARS‐CoV‐2 is yet to be established. SARS‐CoV‐2‐specific antibody responses were evaluated after the first and second dose of the BNT162b2 mRNA vaccine, comparing the response of individuals with AO with the response of those without, and discerning between individuals with or without prior infection.Methods: Immunoglobulin G (IgG)‐neutralizing antibodies against the Trimeric complex (IgG‐TrimericS) were measured at four time points: at baseline, at day 21 after vaccine dose 1, and at 1 and 3 months after dose 2. Nucleocapsid antibodies were assessed to detect prior SARS‐CoV‐2 infection. Waist circumference was measured to determine AO.Results: Between the first and third month after vaccine dose 2, the drop in IgG‐TrimericS levels was more remarkable in individuals with AO compared with those without AO (2.44‐fold [95% CI: 2.22‐2.63] vs. 1.82‐fold [95% CI: 1.69‐1.92], respectively, p < 0.001). Multivariable linear regression confirmed this result after inclusion of assessed confounders (p < 0.001).Conclusions: The waning antibody levels in individuals with AO may further support recent recommendations to offer booster vaccines to adults with high‐risk medical conditions, including obesity, and particularly to those with a more prevalent AO phenotype.


  • Open Access

    Corrigendum to “Tri-Ponderal Mass Index vs body Mass Index in discriminating central obesity and hypertension in adolescents with overweight” [Nutrition, metabolism and cardiovascular diseases 31 (2021) 1613–1621]

    by Alexis E. Malavazos, Gloria Capitanio, Valentina Milani, Federico Ambrogi, Irene A. Matelloni, Sara Basilico, Carola Dubini, Francesca M. Sironi, Elisabetta Stella, Silvana Castaldi, et al.


  • Open Access

    Antibody responses to BNT162b2 mRNA vaccine: infection-naïve individuals with abdominal obesity warrant attention

    by Alexis Elias Malavazos, Sara Basilico, Gianluca Iacobellis, Valentina Milani, Rosanna Cardani, Federico Boniardi, Carola Dubini, Ilaria Prandoni, Gloria Capitanio, Laura Valentina Renna, et al.

    Objective The excess of visceral adipose tissue might hinder and delay the immune response. How people with abdominal obesity will respond to mRNA vaccines against SARS-CoV-2 is yet to be established. We evaluated SARS-CoV-2-specific antibody responses after the first and second dose of the BNT162b2 mRNA vaccine comparing the response of individuals affected by abdominal obesity (AO) to those without, discerning between individuals with or without prior infection. Methods IgG neutralizing antibodies against the Trimeric complex (IgG-TrimericS) were measured at four time points: at baseline, at day 21 after vaccine dose-1, at one month and three months after dose-2. Nucleocapsid antibodies were assessed to detect prior SARS-CoV-2 infection. Waist circumference was measured to determine abdominal obesity. Results Between the first and third month after vaccine dose-2, the drop in IgG-TrimericS levels was more remarkable in individuals with AO compared to those without AO (2.44 fold [95%CI: 2.22-2.63] vs 1.82 fold [95%CI: 1.69-1.92], respectively, pConclusions Our findings highlight the need to extend the duration of serological monitoring of antibody levels in infection-naive individuals with abdominal obesity, a higher-risk population category in terms of possible weaker antibody response.


  • Open Access

    Abdominal obesity phenotype is associated with COVID-19 chest X-ray severity score better than BMI-based obesity

    by Alexis Elias Malavazos, Francesco Secchi, Sara Basilico, Gloria Capitanio, Sara Boveri, Valentina Milani, Carola Dubini, Simone Schiaffino, Lelio Morricone, Chiara Foschini, et al.

    Purpose Chest X-ray (CXR) severity score and BMI-based obesity are predictive risk factors for COVID-19 hospital admission. However, the relationship between abdominal obesity and CXR severity score has not yet been fully explored. Methods This retrospective cohort study analyzed the association of different adiposity indexes, including waist circumference and body mass index (BMI), with CXR severity score in 215 hospitalized patients with COVID-19. Results Patients with abdominal obesity showed significantly higher CXR severity scores and had higher rates of CXR severity scores ≥ 8 compared to those without abdominal obesity (P < 0.001; P = 0.001, respectively). By contrast, patients with normal weight, with overweight and those with BMI-based obesity showed no significant differences in either CXR severity scores or in the rates of CXR severity scores ≥ 8 (P = 0.104; P = 0.271, respectively). Waist circumference and waist-to-height ratio (WHtR) correlated more closely with CXR severity scores than BMI (r = 0.43, P < 0.001; r = 0.41, P < 0.001; r = 0.17, P = 0.012, respectively). The area under the curves (AUCs) for waist circumference and WHtR were significantly higher than that for BMI in identifying a high CXR severity score (≥ 8) (0.68 [0.60–0.75] and 0.67 [0.60–0.74] vs 0.58 [0.51–0.66], P = 0.001). A multivariate analysis indicated abdominal obesity (risk ratio: 1.75, 95% CI: 1.25–2.45, P < 0.001), bronchial asthma (risk ratio: 1.73, 95% CI: 1.07–2.81, P = 0.026) and oxygen saturation at admission (risk ratio: 0.96, 95% CI: 0.94–0.97, P < 0.001) as the only independent factors associated with high CXR severity scores. Conclusion Abdominal obesity phenotype is associated with a high CXR severity score better than BMI-based obesity in hospitalized patients with COVID-19. Therefore, when visiting the patient in a hospital setting, waist circumference should be measured, and patients with abdominal obesity should be monitored closely. Level of evidence Cross-sectional descriptive study, Level V.


  • Open Access

    Comparable Outcomes Between Genders in Patients Undergoing Surgical Ventricular Reconstruction for Ischaemic Heart Failure

    by Serenella Castelvecchio, Valentina Milani, Marianna Volpe, Michele Citarella, Federico Ambrogi, Sara Boveri, Guglielmo Saitto, Andrea Garatti, Lorenzo Menicanti

    Aims Female sex and heart failure (HF) are considered poor prognostic factors for surgery. We aimed to investigate the association between sex and surgical outcomes in patients with ischaemic HF undergoing surgical ventricular reconstruction and coronary artery bypass grafting. Methods and results From July 2001 to June 2017, 648 patients [111 women (17%) and 537 men (83%)] were referred to our centre. Follow‐up continued through June 2018. All patients underwent surgical ventricular reconstruction; coronary artery bypass grafting was performed in 582 patients (90%). Primary outcome was defined as all‐cause mortality. Secondary outcome included all‐cause mortality or all‐cause hospitalization. Women were older (70 vs. 65 years, P < 0.0001) with lower body surface area (1.70 vs. 1.86 m2, P < 0.0001). Women had more diabetes (36% vs. 24%, P = 0.005) and a higher New York Heart Association classification (Class III/IV 65.7% vs. 47.8%, P = 0.0006), without any significant difference in medical therapy except for a higher use of oral antidiabetic agents in women (P = 0.029). At baseline, the left ventricular (LV) end‐diastolic volume index was significantly lower in women [median 107.06 (80.6–127.81) vs. 113. 04 (94.33–135.52) mL/m2, P = 0.0078] but not the LV end‐systolic volume index (ESVI) [median 73.45 (51.93–96.79) vs. 77.03 (60.33–95.71) mL/m2, P = 0.1393] and the ejection fraction (median 31% vs. 32%, P = 0.150). Women had a higher rate of anterior remodelling (90.9% vs. 79.1%, P = 0.0129), without evidence of differences in mitral valve insufficiency (P = 0.761 for Grade 0 to 4) and mitral surgery (P = 0.810). After surgery, the percentage of reduction in LV ESVI was higher in women than in men (median ΔLV ESVI −42.06 vs. −31.99, P = 0.0003). Mortality within 30 days occurred in 43 patients (6.64%): 12 women (10.81%) and 31 men (5.77%, P = 0.0522). Over a median follow‐up of 9.8 years, all‐cause mortality occurred in 269 patients (41.64%), without significant difference between women (45.9%) and men (40.7%). There was no evidence of difference of all‐cause death between sexes (log‐rank = 0.2441). When considering mortality and first hospitalization as competing events, Gray's test showed no difference of cumulative incidence functions (all‐cause hospitalization, all‐cause death, and combined endpoint) according to sex (P = 0.909, P = 0.445, and P = 0.429, respectively). Conclusions In this study, long‐term outcomes for women and men with ischaemic HF undergoing complex cardiac surgery were equivalent. Albeit older and more symptomatic, women should not be denied this type of cardiac surgery.